Published in Drug Metab Pharmacokinet on June 01, 2006
The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. Eur J Clin Pharmacol (2012) 2.12
Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem (2010) 1.60
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet (2008) 1.50
Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys (2009) 1.41
Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome (2010) 1.40
The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy (2013) 1.37
Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J (2009) 1.12
Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Pharmacol (2007) 1.12
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Gene expression analyses in Atlantic salmon challenged with infectious salmon anemia virus reveal differences between individuals with early, intermediate and late mortality. BMC Genomics (2008) 0.96
Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos (2013) 0.92
Release and uptake of volatile organic compounds by human hepatocellular carcinoma cells (HepG2) in vitro. Cancer Cell Int (2013) 0.90
CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Pharmacogenomics J (2015) 0.89
Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. J Biol Chem (2010) 0.87
Polyisoprenylation potentiates the inhibition of polyisoprenylated methylated protein methyl esterase and the cell degenerative effects of sulfonyl fluorides. Curr Cancer Drug Targets (2011) 0.85
Mammalian carboxylesterase 5: comparative biochemistry and genomics. Comp Biochem Physiol Part D Genomics Proteomics (2008) 0.85
Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation. Biochem Pharmacol (2012) 0.85
A comparative 90-day toxicity study of allyl acetate, allyl alcohol and acrolein. Toxicology (2008) 0.84
Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol (2015) 0.84
Mammalian carboxylesterase 3: comparative genomics and proteomics. Genetica (2010) 0.84
Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620. Antimicrob Agents Chemother (2014) 0.83
Homology modeling and metabolism prediction of human carboxylesterase-2 using docking analyses by GriDock: a parallelized tool based on AutoDock 4.0. J Comput Aided Mol Des (2010) 0.83
Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase. Curr Cancer Drug Targets (2010) 0.83
Protein adducts as biomarkers of exposure to organophosphorus compounds. Toxicology (2012) 0.83
Multicolor imaging of endoplasmic reticulum-located esterase as a prodrug activation enzyme. ACS Med Chem Lett (2014) 0.82
Baboon carboxylesterases 1 and 2: sequences, structures and phylogenetic relationships with human and other primate carboxylesterases. J Med Primatol (2009) 0.82
Host-related factors explaining interindividual variability of carotenoid bioavailability and tissue concentrations in humans. Mol Nutr Food Res (2017) 0.81
Organophosphorus flame retardants inhibit specific liver carboxylesterases and cause serum hypertriglyceridemia. ACS Chem Biol (2014) 0.81
Orally administered DTPA penta-ethyl ester for the decorporation of inhaled (241)Am. J Pharm Sci (2014) 0.80
A new class of mammalian carboxylesterase CES6. Comp Biochem Physiol Part D Genomics Proteomics (2009) 0.80
Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Drug Metab Dispos (2016) 0.79
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. Antimicrob Agents Chemother (2015) 0.79
Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother (2009) 0.79
Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag (2009) 0.78
Development of a Novel Formulation that Improves Pre-clinical Bioavailability of Tenofovir Disoproxil Fumarate. J Pharm Sci (2016) 0.78
Horse carboxylesterases: evidence for six CES1 and four families of CES genes on chromosome 3. Comp Biochem Physiol Part D Genomics Proteomics (2008) 0.77
Bovine Carboxylesterases: Evidence for Two CES1 and Five Families of CES Genes on Chromosome 18. Comp Biochem Physiol Part D Genomics Proteomics (2009) 0.77
Quantitative analysis of volatile organic compounds released and consumed by rat L6 skeletal muscle cells in vitro. J Breath Res (2014) 0.76
A novel lactone-forming carboxylesterase: molecular identification of a tuliposide A-converting enzyme in tulip. Plant Physiol (2012) 0.76
Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease. Sci Rep (2015) 0.76
Effects of Mitragynine and a Crude Alkaloid Extract Derived from Mitragyna speciosa Korth. on Permethrin Elimination in Rats. Pharmaceutics (2015) 0.75
Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol (2016) 0.75
Undesired versus designed enzymatic cleavage of linkers for liver targeting. Bioorg Med Chem Lett (2014) 0.75
Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases. J Pharm Sci (2016) 0.75
p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes. Expert Opin Ther Targets (2016) 0.75
Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917. Pharmacol Res Perspect (2015) 0.75
In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2. PLoS One (2014) 0.75
Absorption enhancement of adefovir dipivoxil by incorporating MCT and ethyl oleate complex oil phase in emulsion. Acta Pharmacol Sin (2010) 0.75
Analysis of volatile organic compounds liberated and metabolised by human umbilical vein endothelial cells (HUVEC) in vitro. Cell Biochem Biophys (2015) 0.75
Involvement of Carboxylesterase in Hydrolysis of Propranolol Prodrug during Permeation across Rat Skin. Pharmaceutics (2013) 0.75
Ester-Modified Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents. Sci Rep (2016) 0.75
Structure-Activity Relationships of Pentacyclic Triterpenoids as Potent and Selective Inhibitors against Human Carboxylesterase 1. Front Pharmacol (2017) 0.75
Alkyl 2-arylhydrazinylidene-3-oxo-3-polyfluoroalkylpropionates as new effective and selective inhibitors of carboxylesterase. Dokl Biochem Biophys (2016) 0.75
[Hydrolysis by carboxylesterase and disposition of prodrug with ester moiety]. Yakugaku Zasshi (2007) 0.79